Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Eugenia Sbityakova"'
Autor:
Elza Lomaia, Tamara Chitanava, Yulia Vlasova, Dmitry Motorin, Sergey Voloshin, Darina Zammoeva, Renat Badaev, Yulia Matvienko, Elizaveta Efremova, Ekaterina Mileeva, Nadia Siordia, Olga Kulemina, Eugenia Sbityakova, Natalia Lazorko, Julia Alexeeva, Irina Martynkevich, Elena Karyagina, Natalia Ilyina, Nadezhda Medvedeva, Natalia Dorofeeva, Tatiana Shneider, Svetlana Stepanova, Vasily Shuvaev, Elena Morozova
Publikováno v:
Blood. 140:12192-12193
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01bc3cab6febd4a9848e2cce22652a3e
https://doi.org/10.1182/blood-2022-163506
https://doi.org/10.1182/blood-2022-163506
Autor:
Tamara Chitanava, Vasily Shuvaev, Iuliia Matvienko, Irina Martynkevich, Sergey Voloshin, Elizaveta Efremova, Ekaterina Mileeva, Mikhail Fominykh, Anna Kersilova, Elena Koryagina, Natalia Ilyina, Natalia Dorofeeva, Nadezhda Medvedeva, Anna Klimovich, Tatiana Shneider, Svetlana Stepanova, Natalia Polezhajkovskaya, Nadiya Siordiya, Eugenia Sbityakova, Natalia Lazorko, Elena Tochenaya, Dmitry Motorin, Nadezhda Shnalieva, Yulia Alekseeva, Darina Zammoeva, Elza Lomaia
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S288
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4175b97f4e08e940e3428a262166b7ed
https://doi.org/10.1016/s2152-2650(22)01365-9
https://doi.org/10.1016/s2152-2650(22)01365-9
Autor:
Tamara Chitanava, Agniia-Polina Poshivay, Andrey Zaritskey, Vasily Shuvaev, Nadezhda Shnalieva, Darina Zammoeva, Mikhail Fominykh, Irina Martynkevich, Natalia Polezhajkovskaya, NT Siordiya, Eugenia Sbityakova, Anna Kersilova, Elena Koryagina, Nadezhda Medvedeva, Elena Tochenaya, Svetlana Stepanova, Natalia Ilyina, Elza Lomaia, Natalia Lazorko, Elizaveta Efremova, Olga Merzlikina, Anna Klimovich, Tatiana Shneider, Natalia Dorofeeva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S242
Context Tyrosine kinase inhibitors in third-line therapy (TKI-3L) in chronic-phase chronic myelogenous leukemia (CP CML) is effective in a portion of patients. Meanwhile, it is unclear which patients may benefit from TKI-3L. Objective To identify the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7987f4bcb44d02d1c9d3d8ff5ab1d7ec
https://doi.org/10.1016/s2152-2650(20)30830-2
https://doi.org/10.1016/s2152-2650(20)30830-2
Autor:
Diana Mescheryakova, Eugenia Sbityakova, Vladimir Strugov, Ekaterina Romanova, Nadia Siordia, Elza Lomaia, Andrey Zaritskey, Tatiana Silina, Elena Goriunova, Larisa Girshova, Yulia Alexeeva, Dmitry Motorin, Natalia Lazorko
Publikováno v:
Blood. 122:5173-5173
Dramatic changes in overall survival of patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) have occurred since tyrosine kinase inhibitors (TKIs) were implemented in the treatment strategy. But there are still many issues in ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8991f19986d9e7f98ee2221ada7eb123
https://doi.org/10.1182/blood.v122.21.5173.5173
https://doi.org/10.1182/blood.v122.21.5173.5173
Autor:
Irina Martinkevich, Natalia Ilina, Andrey Zaritskey, Elena Karyagina, Natalia Lazorko, Elza Lomaia, Elena Usacheva, Vera Udalieva, Ekaterina Romanova, Irina Zotova, Tatiana Shneider, Eugenia Sbityakova, Alla Abdulkadyrova, Vasiliy Shuvaev, Kudrat Abdulkadyrov, Elena Machulaitene, Irina Kholopova
Publikováno v:
Blood. 120:4432-4432
Abstract 4432 Background: The incidence of chronic myeloid leukemia (CML), reported from some population based registries, varies significantly. CML is known as age-dependent disease, so population age structure may strongly influent on the data. For
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17fd5ff81f2a344215a0c7f327fc80aa
https://doi.org/10.1182/blood.v120.21.4432.4432
https://doi.org/10.1182/blood.v120.21.4432.4432
Autor:
Elena Koryagina, Irina Zotova, Elza Lomaia, Natalia Ilina, Vasiliy Shuvaev, Andrey Zaritskey, Zvenyslava Masliak, Irina Dyagil, Natalia Lazorko, Natalia Babkina, Irina Dmitrenko, T. Perekhrestenko, Elena Machulaitene, Svetlana Stepanova, Ekaterina Poznyak, Elena Usacheva, Kudrat Abdulkadirov, Irina Martinkevich, Eugenia Sbityakova, Ekaterina Romanova, Alla Abdulkadirova, Elena Goryunova, Maria Ivanova, Vera Udalieva, Tatiana Shneider
Publikováno v:
Blood. 118:4452-4452
Abstract 4452 Imatinib (IM) is now used world-wide as a first line chronic myeloid leukemia (CML) treatment. Although some time lack may exist between diagnosis and IM treatment. Earlier (Blood 2009, 114: Abstract 4278) we have shown that in CML chro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddb01716cabed8d713333cbe913c4f27
https://doi.org/10.1182/blood.v118.21.4452.4452
https://doi.org/10.1182/blood.v118.21.4452.4452